TY - JOUR
T1 - Anticardiolipin and anti-β2GPI antibodies in a large series of European patients with systemic lupus erythematosus
AU - Sebastiani, Gian Domenico
AU - Galeazzi, Mauro
AU - Tincani, Angela
AU - Piette, Jean Charles
AU - Font, Josep
AU - Allegri, Flavio
AU - Mathieu, Alessandro
AU - Smolen, Josef
AU - De Ramon Garrido, Enrique
AU - Fernandez-Nebro, Antonio
AU - Jedryka-Goral, Anna
AU - Papasteriades, Chryssa
AU - Morozzi, Gabriella
AU - Bellisai, Francesca
AU - De Pita, Ornella
AU - Marcolongo, Roberto
PY - 1999
Y1 - 1999
N2 - Objective: To test the prevalences and the clinical associations of anticardiolipin (aCL) and anti-β2GPI (aβ2GPI) antibodies in a large series of European patients with systemic lupus erythematosus (SLE). Methods: 574 SLE patients from 7 European countries were tested for aCL and aβ2GPI by ELISA methods. Results: aCL of IgG, IgM, and IgA isotypes were detected in 22.8%, 14%, and 13.9% of the patients, respectively. IgG and IgM aβ2GPI were detected in 20% of the patients. The presence of aCL was highly associated with the presence of aβ2GPI. Medium-high titer IgG aCL and aβ2GPI were associated with thrombosis, with similar sensitivity, specificity, and positive predictive value. When present at medium-high titer, IgG aCL were associated with thrombocytopenia, IgM aCL with hemolytic anemia, and cerebrovascular accidents, IgA aCL with livedo reticularis and Raynaud's phenomenon. Conclusions: aCL, when present at medium-high titer, are as important as aβ2GPI, as a risk factor for thrombosis. Medium-high titer aCL, but not aβ2GPI, are associated with other clinical features of the antiphospholipid syndrome.
AB - Objective: To test the prevalences and the clinical associations of anticardiolipin (aCL) and anti-β2GPI (aβ2GPI) antibodies in a large series of European patients with systemic lupus erythematosus (SLE). Methods: 574 SLE patients from 7 European countries were tested for aCL and aβ2GPI by ELISA methods. Results: aCL of IgG, IgM, and IgA isotypes were detected in 22.8%, 14%, and 13.9% of the patients, respectively. IgG and IgM aβ2GPI were detected in 20% of the patients. The presence of aCL was highly associated with the presence of aβ2GPI. Medium-high titer IgG aCL and aβ2GPI were associated with thrombosis, with similar sensitivity, specificity, and positive predictive value. When present at medium-high titer, IgG aCL were associated with thrombocytopenia, IgM aCL with hemolytic anemia, and cerebrovascular accidents, IgA aCL with livedo reticularis and Raynaud's phenomenon. Conclusions: aCL, when present at medium-high titer, are as important as aβ2GPI, as a risk factor for thrombosis. Medium-high titer aCL, but not aβ2GPI, are associated with other clinical features of the antiphospholipid syndrome.
KW - aβGPI
KW - aCL
KW - Antiphospholipid syndrome
KW - Systemic lupus erythematosus
UR - http://www.scopus.com/inward/record.url?scp=0033256156&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0033256156&partnerID=8YFLogxK
M3 - Article
C2 - 10665739
AN - SCOPUS:0033256156
VL - 28
SP - 344
EP - 351
JO - Scandinavian Journal of Rheumatology
JF - Scandinavian Journal of Rheumatology
SN - 0300-9742
IS - 6
ER -